Geney Bio

Geney Bio is developing a low-cost, automated platform for cell therapy manufacturing from preclinical development through to commercial production. By enabling parallel experimentation, it helps developers create more robust processes in one-quarter of the time, avoid costly redevelopment between stages and reduce development and commercial manufacturing costs by up to 80%. Revenue will come from equipment, recurring consumables, services and commercial licensing.

Developing regulatory-compliant manufacturing processes for cell therapies can cost AU$2–7 million and take over a year. Existing platforms are designed for preclinical, clinical or commercial-scale manufacturing, forcing costly redevelopment at each stage. Combined with high manufacturing costs, this consumes scarce startup capital and drives the AU$500K+ therapy price.

Organisations developing regulatory-compliant manufacturing processes for cell therapies between preclinical development and early Phase II, after selecting a lead asset but before locking the process.

• Built on AU$8M of R&D at UNSW
• AU$1M pre-committed funding for upcoming pre-seed round
• RPA and Royal Perth Hospital pilots scheduled